Skip to content
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Neurology

How Are FFI Agitation, Hallucinations, and Dreams Managed?

At a Glance

In fatal familial insomnia, hallucinations, agitation, and dream-like episodes are managed by keeping the environment calm and safe, checking for treatable causes of sudden worsening, and using carefully monitored medicines or palliative sedation when distress cannot otherwise be relieved.

In fatal familial insomnia (FFI), hallucinations, severe agitation, and dream-like episodes are managed through a combination of creating a calm environment, ruling out sudden medical triggers, and, when necessary, using carefully monitored medications [1][2][3]. FFI is a rare prion disease that heavily affects the thalamus and networks in the brain controlling sleep and autonomic (involuntary) functions [4]. Because of this damage, some patients experience a syndrome called agrypnia excitata—a profound state of sleep disruption combined with constant physical and involuntary overactivity, which blurs the lines between being awake and dreaming [5][6]. While these dream-like (oneiroid) states can be deeply frightening, focusing on comfort, routine, and palliative symptom relief can help minimize distress for both the patient and their family [4].

Checking for Hidden Triggers (Delirium)

It is common to assume that new or worsening confusion, agitation, or hallucinations are just the natural progression of FFI. However, an abrupt, fluctuating change in awareness is often caused by delirium, a state of sudden, severe confusion triggered by physical stress on the body [7][8]. Not every hallucination in FFI is delirium, but sudden changes require evaluation. Before starting or increasing sedating medications, clinicians should systematically check for and treat these hidden triggers, provided doing so aligns with the patient’s goals of care [9][10]:

  • Infections: A urinary tract infection, pneumonia, or other illness can cause a sudden spike in confusion and agitation [11].
  • Pain and Discomfort: The patient may be in severe pain but unable to express it clearly. Checking for sources of pain is a critical first step [2].
  • Urinary Retention and Constipation: A full bladder that cannot empty or severe constipation can cause extreme physical distress and agitation [2][12].
  • Dehydration and Poor Oxygenation: Lack of fluids or low blood oxygen (hypoxia) can rapidly worsen mental clarity [11].
  • Medication Side Effects: Certain drugs, particularly opioids or those with anticholinergic properties (medications that block certain nerve impulses, like some allergy or overactive bladder drugs), can inadvertently cause or worsen delirium [13].

Calm Communication and Environment

For many FFI patients, environmental measures are a vital first step that may help reduce daily anxiety and agitation [1]. While they do not replace medical assessment for sudden changes, these strategies help make the environment feel secure and predictable:

  • Provide a Low-Stimulation Space: Keep the room quiet, use comfortable, even lighting to provide day-night cues (excessive shadows can worsen visual misperceptions), and reduce background noise to avoid overwhelming the patient [14].
  • Use Familiar Voices and Faces: The presence of trusted family members and familiar objects can help orient the patient. However, avoid large crowds or visitors who might inadvertently increase agitation [15][16].
  • Avoid Arguments and Corrections: If the patient is having a hallucination or is stuck in a dream-like state, do not argue with them or try to force them into reality. Instead, validate their distress, offer gentle reassurance, and calmly redirect the conversation [17].
  • Safety Without Sudden Restraints: Caregivers should never tie the patient down or use physical restraints themselves, as this can drastically increase fear and worsen agitation [18]. Instead, remove dangerous objects, maintain a safe distance, use one calm speaker to redirect them, and call the care team for help. Trained clinicians only use the least restrictive interventions as an absolute last resort for imminent danger [1].

Medical Options for Severe Distress

When non-drug methods and trigger checks are not enough to calm severe distress or unsafe behaviors, a doctor or a palliative care clinician with neurologic expertise may introduce medications [3]. Because FFI is exceptionally rare, there is no proven, FFI-specific medication regimen. Limited case reports show that standard antipsychotic and sedative medications sometimes offer little benefit, and a few patients have experienced extreme negative physical reactions (sometimes called neuroleptic hypersensitivity) [19][20]. Therefore, any medication must be heavily individualized and used cautiously:

  • Sedatives and Anti-Anxiety Medications: Drugs like lorazepam or midazolam may be used in palliative care to help manage severe, persistent agitation when other methods fail [3][21]. However, they carry risks of oversedation, paradoxical disinhibition (causing more agitation instead of less), and dangerously slow breathing [21].
  • Antipsychotics: Medications like haloperidol are sometimes utilized for severe distress, though they must be monitored closely as they can occasionally worsen symptoms or cause akathisia (a severe inner restlessness that looks like worsening agitation) and other movement problems [22].
  • Specialist Inpatient Options: In a supervised hospital or intensive hospice setting, specialist drugs like dexmedetomidine might be considered. While it can sometimes keep a patient calm but still rousable (able to be woken up), it requires intense monitoring because it can cause dangerously low heart rates and blood pressure [23][24].
  • Palliative Sedation: If agitation and distress become entirely refractory (unmanageable despite all treatments), the medical team may discuss palliative sedation. This involves using medications to intentionally lower the patient’s awareness to relieve suffering, prioritizing comfort over wakefulness [25][26].

Advance Planning and When to Seek Urgent Help

Because FFI can progress rapidly and affect communication, it is vital to engage in advance care planning early. Families should identify a substitute decision-maker and document preferences about hospitalization, resuscitation, the use of heavy sedation, and how safety crises should be handled while the patient can still participate in the conversation.

Work with your clinician to define a step-by-step crisis plan. You should seek urgent help according to that plan if:

  • The patient experiences a sudden, dramatic change in behavior, alertness, or confusion.
  • You suspect an infection, fever, or pain, or if the patient is unable to urinate for an extended period.
  • Their breathing becomes dangerously slow, shallow, or irregular, or they have blue/gray lips (call emergency services or your emergency hospice line immediately).
  • They are acting in a way that is immediately unsafe to themselves or others and cannot be safely redirected.

Common questions in this guide

What should I do when someone with FFI is hallucinating or seems stuck in a dream?
Use one calm speaker, reduce noise and shadows, and offer familiar reassurance. Do not argue about what the person sees or force them to accept reality; acknowledge that they are frightened and gently redirect them while removing hazards.
Can a sudden increase in agitation be caused by something treatable?
Yes. An abrupt or fluctuating change can be delirium, so clinicians may check for infection, pain, urinary retention, constipation, dehydration, low oxygen, or medication effects while considering the patient’s goals of care.
What medicines can help severe agitation in fatal familial insomnia?
There is no proven FFI-specific medication regimen. In palliative or specialist care, clinicians may consider lorazepam or midazolam, haloperidol, or dexmedetomidine in a closely monitored inpatient setting. These medicines can cause excessive sleepiness, slowed breathing, low blood pressure, movement problems, or worsening restlessness, so they require individualized monitoring.
When is palliative sedation considered for FFI?
It may be discussed when severe distress remains unmanageable despite appropriate comfort measures and medication. Palliative sedation intentionally lowers awareness to relieve suffering and prioritizes comfort over wakefulness; it should be guided by the palliative or hospice team and the patient’s documented goals.
When should we seek emergency help for FFI agitation or confusion?
Seek urgent help for a sudden dramatic change, suspected infection or fever, severe pain, prolonged inability to urinate, or behavior that cannot be safely redirected. Call emergency services or the emergency hospice line immediately for dangerously slow, shallow, or irregular breathing or blue or gray lips.
Why should families make an advance care plan early in FFI?
Fatal familial insomnia can progress quickly and may impair communication, so the patient may later be unable to express preferences. Early planning can name a substitute decision-maker and document wishes about hospitalization, resuscitation, medication, safety crises, and palliative sedation.

Get notified when new evidence is published on Fatal familial insomnia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.

    Burton JK, Craig L, Yong SQ, et al.

    The Cochrane database of systematic reviews 2021; (11()):CD013307 doi:10.1002/14651858.CD013307.pub3.

    PMID: 34826144
  2. 2

    Hospice Clinicians' Approaches to Terminal Restlessness: A Qualitative Analysis.

    Jan A, Turnwald M, Maixner S, et al.

    Journal of pain and symptom management 2026; (71(4)):567-573.e1 doi:10.1016/j.jpainsymman.2025.12.028.

    PMID: 41500370
  3. 3

    Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial.

    Hui D, De La Rosa A, Tsai JS, et al.

    JAMA oncology 2025; (11(9)):1031-1043 doi:10.1001/jamaoncol.2025.2212.

    PMID: 40742738
  4. 4

    Fatal insomnia: the elusive prion disease.

    Patel D, Ibrahim H, Rankin J, et al.

    BMJ case reports 2021; (14(6)) doi:10.1136/bcr-2020-241289.

    PMID: 34158325
  5. 5

    Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications.

    Baldelli L, Provini F

    Autonomic neuroscience : basic & clinical 2019; (218()):68-86 doi:10.1016/j.autneu.2019.02.007.

    PMID: 30890351
  6. 6

    Agrypnia excitata: a human model to explore the derailment of sleep-wake cycle integrated control.

    Mutti C, Baldelli L, Cortelli P, et al.

    Journal of sleep research 2025; (34(2)):e14324 doi:10.1111/jsr.14324.

    PMID: 39223838
  7. 7

    Diagnosis of delirium: a practical approach.

    Alexander SK, Needham E

    Practical neurology 2023; (23(3)):192-199 doi:10.1136/pn-2022-003373.

    PMID: 36581459
  8. 8

    Agitation and delirium in the last days of life: terminology and management-systematic review and narrative synthesis.

    Hatton RA, Erez G, Johnson MJ

    BMJ supportive & palliative care 2026; doi:10.1136/spcare-2025-005872.

    PMID: 42448443
  9. 9

    Palliative sedation at the end of life: Practical and ethical considerations.

    Barry C, Brodrick R, Gupta G, Panjwani I

    Clinical medicine (London, England) 2025; (25(4)):100338 doi:10.1016/j.clinme.2025.100338.

    PMID: 40523526
  10. 10

    Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.

    Agar MR, Lawlor PG, Quinn S, et al.

    JAMA internal medicine 2017; (177(1)):34-42 doi:10.1001/jamainternmed.2016.7491.

    PMID: 27918778
  11. 11

    Reversibility of delirium in Ill-hospitalized cancer patients: Does underlying etiology matter?

    Matsuda Y, Maeda I, Morita T, et al.

    Cancer medicine 2020; (9(1)):19-26 doi:10.1002/cam4.2669.

    PMID: 31696671
  12. 12

    Should This Patient Receive Prophylactic Medication to Prevent Delirium?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

    Tess AV, Mattison MLP, Leo JR, Reynolds EE

    Annals of internal medicine 2018; (168(7)):498-505 doi:10.7326/M18-0388.

    PMID: 29610916
  13. 13

    Delirium.

    Wilson JE, Mart MF, Cunningham C, et al.

    Nature reviews. Disease primers 2020; (6(1)):90 doi:10.1038/s41572-020-00223-4.

    PMID: 33184265
  14. 14

    Prevention and management of delirium in critically ill adult patients in the intensive care unit: a review based on the 2018 PADIS guidelines.

    Park SY, Lee HB

    Acute and critical care 2019; (34(2)):117-125 doi:10.4266/acc.2019.00451.

    PMID: 31723916
  15. 15

    The effectiveness of family participation interventions for the prevention of delirium in intensive care units: A systematic review.

    Vitorino ML, Henriques A, Melo G, Henriques HR

    Intensive & critical care nursing 2025; (89()):103976 doi:10.1016/j.iccn.2025.103976.

    PMID: 40024138
  16. 16

    [Update on the diagnosis and treatment of delirium].

    Sadlonova M, von Arnim CAF

    Innere Medizin (Heidelberg, Germany) 2023; (64(9)):855-863 doi:10.1007/s00108-023-01561-7.

    PMID: 37540259
  17. 17

    Family intervention improves outcomes for patients with delirium: Systematic review and meta-analysis.

    McKenzie J, Joy A

    Australasian journal on ageing 2020; (39(1)):21-30 doi:10.1111/ajag.12688.

    PMID: 31250961
  18. 18

    Effectiveness of the In-Hospital Information Technology System-Based Delirium Management Intervention Program in Medically Hospitalized Patients with Dementia: A Retrospective Case-Control Study.

    Wang SC, Wang WF, Chang MC, et al.

    Journal of multidisciplinary healthcare 2025; (18()):6745-6754 doi:10.2147/JMDH.S542781.

    PMID: 41127385
  19. 19

    A fatal familial insomnia patient newly diagnosed as having depression: A case report.

    Yukang T, Jiaquan L, Xiaoling L, et al.

    Medicine 2021; (100(41)):e27544 doi:10.1097/MD.0000000000027544.

    PMID: 34731156
  20. 20

    Clinical Manifestations.

    Teixeira MS, Gomes AM, Epifanio HB, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21 Suppl 3()):e102926 doi:10.1002/alz70857_102926.

    PMID: 41447306
  21. 21

    Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication.

    Hui D

    Current opinion in supportive and palliative care 2018; (12(4)):489-494 doi:10.1097/SPC.0000000000000395.

    PMID: 30239384
  22. 22

    Drug therapy for delirium in terminally ill adults.

    Finucane AM, Jones L, Leurent B, et al.

    The Cochrane database of systematic reviews 2020; (1()):CD004770 doi:10.1002/14651858.CD004770.pub3.

    PMID: 31960954
  23. 23

    Dexmedetomidine Versus Midazolam for End-of-Life Sedation: The DREAMS Non-Blinded Randomized Clinical Trial.

    Thomas B, Barclay G, Mansfield K, et al.

    Journal of pain and symptom management 2025; (70(5)):459-469 doi:10.1016/j.jpainsymman.2025.07.027.

    PMID: 40769281
  24. 24

    Dexmedetomidine: a magic bullet on its way into palliative care-a narrative review and practice recommendations.

    Gaertner J, Fusi-Schmidhauser T

    Annals of palliative medicine 2022; (11(4)):1491-1504 doi:10.21037/apm-21-1989.

    PMID: 35400162
  25. 25

    Palliative Sedation for the Terminally Ill Patient.

    Garetto F, Cancelli F, Rossi R, Maltoni M

    CNS drugs 2018; (32(10)):951-961 doi:10.1007/s40263-018-0576-7.

    PMID: 30259395
  26. 26

    Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study.

    Won YW, Chun HS, Seo M, et al.

    Journal of pain and symptom management 2019; (58(1)):65-71 doi:10.1016/j.jpainsymman.2019.04.019.

    PMID: 31026509

This page is for informational purposes only and does not constitute medical advice about fatal familial insomnia. Decisions about medications, urgent evaluation, and palliative sedation should be made with the patient’s neurologist, hospice, or palliative care team.